Understanding Donor Blood Antibodies: Risks and Compatibility

In blood transfusion, donor plasma antibodies (primarily anti-A, anti-B, and others) can cause hemolytic transfusion reactions if incompatible with recipient antigens. They cannot be ignored.

Antibody Sources in Donor Blood

  • Whole blood / RBC units: Residual plasma contains donor antibodies (especially high-titer anti-A/B in group O donors).
  • Platelet concentrates: High plasma volume → significant antibody load.
  • Plasma products (FFP, cryo): Entirely plasma — full antibody complement.

Clinical Risks

ScenarioRiskExample
Group O RBC → non-O recipientMinor hemolytic reactionAnti-A/B in donor plasma attacks recipient A/B antigens → mild extravascular hemolysis, positive DAT
Group O platelets → A/B/AB recipientSignificant hemolysisHigh-titer anti-A/B in platelet plasma → acute intravascular hemolysis, hemoglobinuria, DIC, renal failure
Plasma transfusionMajor incompatibilityDonor anti-A given to group A recipient → severe hemolysis

Mitigation Strategies

  • ABO-identical transfusion whenever possible.
  • Low-titer group O whole blood / RBCs (anti-A/B <1:256) for emergency release.
  • Platelet ABO matching: ABO-identical preferred; if not, use "low-titer" or volume-reduced / plasma-depleted platelets.
  • Plasma compatibility: Donor plasma must lack antibodies against recipient red cells (e.g., group AB plasma = universal donor for plasma — no anti-A/B).
  • Irradiation, leukoreduction: Prevent TA-GVHD, HLA alloimmunization, CMV — do not remove antibodies.

Other Clinically Significant Antibodies

  • Anti-Kell, -Duffy, -Kidd, -Rh in multiparous/multiply transfused donors — can cause delayed hemolytic transfusion reactions (DHTR) in antigen-positive recipients.
  • Donor screening does not routinely test for these; recipient antibody screen detects recipient alloantibodies, not donor.

Key Principle

Transfusion compatibility is bidirectional. Recipient antibodies vs. donor antigens (major crossmatch) AND donor antibodies vs. recipient antigens (minor side) both matter. Modern practice minimizes plasma in RBC/platelet products and uses ABO matching to mitigate risk.

Blood Disorders - Related Articles